Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,391,094

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,391,094 protect, and when does it expire?

Patent 10,391,094 protects INREBIC and is included in one NDA.

This patent has thirty-seven patent family members in twenty-five countries.

Summary for Patent: 10,391,094
Title:Compositions and methods for treating myelofibrosis
Abstract: Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyr- imidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
Inventor(s): Jayan; Arvind (La Jolla, CA), Cacace; Janice (Miami, FL)
Assignee: Impact Biomedicines, Inc. (Summit, NJ)
Application Number:13/888,096
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,391,094

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Impact INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327-001 Aug 16, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,391,094

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010363329 ⤷  Try it Free
Australia 2011323108 ⤷  Try it Free
Brazil 112013011184 ⤷  Try it Free
Canada 2816710 ⤷  Try it Free
Canada 2816957 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.